Business
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), that is advancing Eltoprazine into a Phase 2b clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced that it will be presenting a summary of its pending Phase 2b PD-LID clinical program and participating in the neuroscience panel at the Sachs BioCapital USA Forum on March 21, 2018 at the New York Academy of Sciences (NYAS) in New York City. The neuroscience panel is entitled \"Renewed Approaches for Neuroscience.\"\n \"Sachs BioCapital USA Forum is an ideal venue for Elto Pharma to engage with the investment and partnering community,\" said Gerald Commissiong, interim-CEO of Elto Pharma. Presentation Details Company: Elto Pharma (an Amarantus company) Event: Sachs BioCapital USA Forum Date: Wednesday, March 21, 2018 Time:  2:20 p.m. EDT for 20 minutes Presentation Track: Track C Webcast:  Please check www.amarantus.com for details prior to the event Location:  New York Academy of Sciences, New York, NY About Elto Pharma, Inc. Elto Pharma, Inc. is developing Eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile, with statistically significant efficacy results across multiple central nervous system indications. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID. Eltoprazine was originally developed by Solvay (now Abbvie) in aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID. In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. to for the purpose of raising capital to finance the further clinical development of Eltoprazine. About Amarantus Bioscience Holdings, Inc. Amara...